BioSpace News Archive

The rise in awareness about oral care and the growing cases of periodontal illnesses and tooth caries all across the world have prompted the advancement of the expert dental care market.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global oncology biosimilars market is expected to surge nearly 3x across the 2022-2032 forecast period, reaching US$ 12 Billion.

Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company, announced positive topline results for the phase 3 ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus.

Croda International Plc announces that it has entered into a cooperative agreement with the United States government in which the government will provide up to $75 million to expand the company’s U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines.

XNK Therapeutics AB announced it is initiating a program targeting urothelial cancer, the most common form of bladder cancer.

Illumina, Inc. announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health.

Mainz Biomed N.V. announced it has enrolled the first patient in ColoFuture, an international clinical study assessing the potential to integrate a portfolio of novel gene expression biomarkers into ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer which is being commercialized across Europe.

DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the company’s SYNTAX System DNA printer.

Roivant Sciences Ltd. reported its financial results for the fourth quarter and fiscal year ended March 31, 2022 and provided an update on the Company’s operations.

Pyxis Oncology, Inc., an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, announced that the Company will present at the H.C. Wainwright Preclinical Cancer Drug Discovery - Antibody Drug Conjugates virtual conference.